Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
GMP-Manufactured Batch to be Delivered in
Human Dosing Expected to Begin in Summer 2020
“Arcturus had a very productive meeting with the HSA where the clinical development plan was discussed in detail. We foresee continuing to work with the HSA in a collaborative fashion as we approach initiation of the first clinical trial,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
LUNAR-COV19 is a very low dose, potential single-shot (i.m.), self-replicating mRNA vaccine that is devoid of any viral material or co-adjuvants. Utilizing Arcturus processes, the mRNA vaccine product is readily manufactured, with the initial GMP batch to be delivered in June. Preclinical in vitro data shows that administration of LUNAR-COV19 generates effective expression of the COVID-19 virus spike protein – the antigen to which protective antibodies will be formed.
Founded in 2013 and based in
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, including those regarding strategy, future operations, collaborations, the likelihood of success of the Company’s Coronavirus (COVID-19) vaccine or other products, the status of preclinical and clinical development programs, the delivery of any product or substance, the likelihood that preclinical data will be predictive of clinical data, and the planned initiation of clinical trials are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended
Source: Arcturus Therapeutics Holdings Inc.